Imvotamab
As of the edition of 20 October 2026, Imvotamab is an antibody: stopped in 2025; acts on MS4A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 5, 4 stopped early
- Disease areas
- Immune system; Bones, joints and muscles; Skin and connective tissue; Blood and lymph; Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Imvotamab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MS4A1 | B-lymphocyte antigen CD20 | P11836 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 0 | 0 | 3 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Concentra Biosciences | Lead sponsor of trials | 2024 to now |